These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37276081)

  • 1. Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.
    Pasca S; Guo MZ; Wang S; Stokvis K; Shedeck A; Pallavajjala A; Shams C; Pallavajjala R; DeZern AE; Varadhan R; Gocke CD; Jones RJ; Gondek LP
    Blood Adv; 2023 Aug; 7(16):4660-4670. PubMed ID: 37276081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients.
    Kernan NA; Klein E; Mauguen A; Torok-Castanza J; Prockop SE; Scaradavou A; Curran K; Spitzer B; Cancio M; Ruggiero J; Allen J; Harris A; Oved J; O'Reilly RJ; Boelens JJ
    Transplant Cell Ther; 2024 Jul; 30(7):692.e1-692.e12. PubMed ID: 38643958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
    Wong ZC; Dillon LW; Hourigan CS
    Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
    Heuser M; Heida B; Büttner K; Wienecke CP; Teich K; Funke C; Brandes M; Klement P; Liebich A; Wichmann M; Neziri B; Chaturvedi A; Kloos A; Mintzas K; Gaidzik VI; Paschka P; Bullinger L; Fiedler W; Heim A; Puppe W; Krauter J; Döhner K; Döhner H; Ganser A; Stadler M; Hambach L; Gabdoulline R; Thol F
    Blood Adv; 2021 May; 5(9):2294-2304. PubMed ID: 33929500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
    Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
    Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.
    Wienecke CP; Heida B; Venturini L; Gabdoulline R; Krüger K; Teich K; Büttner K; Wichmann M; Puppe W; Neziri B; Reuter M; Dammann E; Stadler M; Ganser A; Hambach L; Thol F; Heuser M
    Blood; 2024 Jul; 144(3):296-307. PubMed ID: 38669617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
    J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Gaut D; Mead M
    Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
    Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
    Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
    Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
    Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors.
    Herr MM; Balderman SR; Wallace PK; Zhang Y; Tario JD; Buxbaum NP; Holtan S; Ross M; McCarthy PL; Betts B; Maslak P; Hahn TE
    Transplant Cell Ther; 2024 Aug; 30(8):808.e1-808.e13. PubMed ID: 38801976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation.
    Waterhouse M; Pennisi S; Pfeifer D; Scherer F; Zeiser R; Duyster J; Bertz H; Finke J; Duque-Afonso J
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
    Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
    JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.